Preview Mode Links will not work in preview mode
  1. All Episodes
  2. HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy (Companion Faculty Lecture)

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy (Companion Faculty Lecture)

Jul 17, 2026

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics:

·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00)

·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of first-line treatment and maintenance approaches for HER2-positive mBC (5:26)

·      Efficacy and safety findings from the Phase III DESTINY-Breast09 trial comparing trastuzumab deruxtecan with or without pertuzumab to taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC (14:56)

·      Predictors of long-term benefit from first-line treatment with HER2-targeted agents; contribution of pertuzumab to the efficacy of first-line HER2-targeted combination regimens (22:57)

·      Control of brain metastases and CNS disease with first-line HER2-targeted regimens (26:31)

CME information and select publications